Neurotech Publishes Positive Phase I/II ASD Trial Results

Neurotech International Ltd. ( (AU:NTI) ) just unveiled an update.

Neurotech International Limited announced the publication of its Phase I/II autism spectrum disorder (ASD) clinical trial results in the journal Advances in Complimentary and Alternative Medicine. The study, led by Professor Michael Fahey, demonstrated that the company’s cannabinoid drug therapy, NTI164, is safe and well-tolerated in children with ASD, showing significant efficacy in improving disruptive behaviors and reducing anxiety. This publication marks an important step in establishing scientific evidence for Neurotech’s programs, potentially enhancing patient safety and health outcomes in the long term.

More about Neurotech International Ltd.

Neurotech International Limited is a clinical-stage biopharmaceutical development company focused primarily on pediatric neurological disorders. The company is developing a broad-spectrum oral cannabinoid drug therapy called NTI164, which has shown clinically meaningful and statistically significant benefits in clinical trials for Autism Spectrum Disorder (ASD), PANDAS/PANS, and Rett Syndrome. Neurotech has also received clearance for a Phase I/II clinical trial in spastic cerebral palsy.

YTD Price Performance: -32.73%

Average Trading Volume: 722,805

Technical Sentiment Signal: Buy

Current Market Cap: A$38.56M

For a thorough assessment of NTI stock, go to TipRanks’ Stock Analysis page.